The Return on Investment for Preventive Healthcare Programmes
May 30, 2017
The report summarises the existing evidence on the effectiveness of workplace related preventive health programmes, outlining the challenges involved in calculating their return on investment (ROI). The report outlines the drivers of successful workplace health promotion programmes and develops a framework to analyse the ROI of such projects.
A calculation framework for GSK's Partnership for Prevention (P4P)
|PDF file||1.2 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
Workplace preventive health initiatives are growing in number and scope around the world, as employers increasingly realise the link between employee health and wellbeing and company's performance. The simple logic is that effective investment in health and wellbeing can save a company more than it spends on the interventions through reduced productivity losses due to lower absenteeism and presenteeism, and lower healthcare spending overall.
Multiple health promotion programmes are taking place in a number of pharmaceutical companies. In general, the goal of these programme are to improve the health and wellbeing of employees by: providing healthcare support; providing healthy lifestyle alternatives; developing a workplace culture that promotes and provides support for healthy living; and, considering the mental health needs of employees.
GSK's Partnership for Prevention (P4P) aims to provide all GSK employees and their benefits-eligible dependants access to preventive healthcare services. Some GSK employees work in countries where publicly funded preventive healthcare may be unavailable or limited and this is where P4P bridges a gap. Some of the interventions, particularly those aimed at smoking cessation or lowering blood pressure and cholesterol, go beyond a simple substitution of necessary preventive healthcare services and aim to improve employees' wellbeing, as well as preventing possible future health complications.
The report outlines the drivers of successful workplace health promotion programmes, provides an overview of health and wellbeing interventions offered by pharmaceutical companies, and develops a framework to analyse the return on investment of such projects, applying it to GSK's P4P programme.
Drivers of a successful workplace health prevention programme
The challenges in measuring returns on investments for preventive healthcare programmes
Evidence on the effectiveness of workplace health prevention programmes and interventions
A framework to calculate the ROI of preventive healthcare programmes
Further details on the literature review
Overview of studies used to inform the development of the calculation tool
Parameters used in the ROI calculation
Calculation tool manual
The research described in this report was funded by GlaxoSmithKline (GSK) conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.